FDA approves Eisai's drug Halaven for type of soft tissue cancer
Advertisement
The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea sponge for a rare type of soft tissue cancer which has no approved treatment so far.
The drug, Halaven, was approved for use in patients who have undergone chemotherapy with drugs derived from a type of bacteria, the FDA said on Thursday. Halaven, derived from a marin e sponge called Halichondria okadai, was approved in 2010 for treating advanced breast cancer.
Liposarcoma affects fat cells in soft tissues such as muscles, tendons, blood vessels, lymph vessels and nerves, and the tumor cannot be removed through surgery.
In a late-stage study, patients receiving Halaven had survival rate of 15.6 months compared with 8.4 months for those given chemotherapy drug, dacarbazine.
The drug, Halaven, was approved for use in patients who have undergone chemotherapy with drugs derived from a type of bacteria, the FDA said on Thursday. Halaven, derived from a marin e sponge called Halichondria okadai, was approved in 2010 for treating advanced breast cancer.
Liposarcoma affects fat cells in soft tissues such as muscles, tendons, blood vessels, lymph vessels and nerves, and the tumor cannot be removed through surgery.
In a late-stage study, patients receiving Halaven had survival rate of 15.6 months compared with 8.4 months for those given chemotherapy drug, dacarbazine.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.